{"prompt": "['Reaction', 'Frequency in ASTRAL-1', 'Headache', '22%', 'Fatigue', '15%', 'Nausea', '9%', 'Asthenia', '5%', 'Insomnia', '5%', 'Co-administration of amiodarone with Epclusa is not recommended because post-marketing cases of', 'symptomatic bradycardia, as well as fatal cardiac arrest and cases requiring pacemaker intervention,', 'have been reported when amiodarone is co-administered with sofosbuvir.', 'The concomitant use of Epclusa with P-gp inducers and/or moderate to potent CYP2B6, CYP2C8, and', \"CYP3A4 (e.g., rifampin, St. John's wort, carbamazepine) may significantly decrease plasma\", 'concentrations of velpatasvir and/or sofosbuvir and may lead to a reduced therapeutic effect of', 'EPCLUSA. Therefore, the use of Epclusa with P-gp inducers and moderate to potent CYP2B6, CYP2C8, and', 'CYP3A4 is not recommended.', 'Velpatasvir solubility decreases as pH increases. Drugs that increase gastric pH are expected to decrease', 'the concentration of velpatasvir. Epclusa and antacid administration must be separated by at least 4', 'hours. H-2 receptor antagonists may be administered simultaneously with or 12 hours apart from', 'Epclusa at a dose that does not exceed famotidine 20 mg BID. Co-administration of Epclusa and proton', 'pump inhibitors is not recommended. However, if it is medically necessary to administer Epclusa and a', 'proton pump inhibitor, Epclusa should be taken with food 4 hours before omeprazole at a dose which', 'does not exceed 20 mg.', 'Epclusa interacts with several medications commonly used by our target population. Efavirenz and', 'tipranavir/r should not be co-administered with Epclusa because these HIV medications decrease', 'velpatasvir and/or sofosbuvir levels. Renal function should be monitored in patients taking tenofovir DF', 'with Epclusa. Epclusa increases levels of the HMG-CoA reductase inhibitors, rosuvastatin and', 'atorvastatin. Patients on atorvastatin and rosuvastatin should be monitored closely for evidence of', 'myopathy; and the dose of rosuvastatin should not exceed 10 mg and the dose of atorvastatin should', 'not exceed 20 mg.', 'Epclusa should not be administered in conjunction with the following medications:', '-', 'Proton pump inhibitors (other than omeprazole 20 mg as above)', '- Amiodarone', '- Digoxin', '- Topotecan', '- Carbamazepine', '- Phenytoin', '- Phenobarbital', '- Oxcarbazepine', '- Rifabutin', '-', 'Rifampin', '- Rifapentine', '- Efavirenz', '- Tipranavir/ritonavir', 'CRI 15-05 Protocol 13SEP2017', 'Page 15'][\"- St. John's Wort\", '-', 'Sofosbuvir as a single agent', 'The efficacy of Epclusa in treatment na\u00efve and treatment experienced (with pegylated interferon and', 'RBV Protease inhibitor) non-cirrhotics and compensated cirrhotics was evaluated in three Phase 3 trials', 'of 1035 subjects with genotypes 1, 2, 3, 4, 5 and 6.', 'ASTRAL-1: Randomized placebo controlled trial of Epclusa for 12 weeks in subjects with', 'genotypes 1, 2, 4, 5, 6', 'ASTRAL-2: Randomized controlled open label trial of Epclusa for 12 weeks compared with', 'SOF/RBV for 12 weeks in subjects with genotype 2', 'ASTRAL-3: Randomized controlled open label trial of Epclusa for 12 weeks compared with', 'SOF/RBV for 24 weeks in subjects with genotype 3', 'Week 12 sustained virologic response (SVR-12) rates for subjects treated in ASTRAL-1 with Epclusa for 12', 'weeks are shown in the table below', 'ASTRAL-1 Virologic Outcomes', 'Genotype (n)', 'SVR-12', '1a (210)', '98%', '1b (118)', '99%', '2 (104)', '100%', '4 (116)', '100%', '5 (35)', '97%', '6 (41)', '100%', 'Week 12 sustained virologic response (SVR-12) rates for genotype 3 subjects treated in ASTRAL-3 with', 'Epclusa for 12 weeks or SOF/RBV for 24 weeks are shown in the table.', 'ASTRAL-3 Virologic Outcomes', 'SVR 12 for Epclusa for 12 weeks', 'SVR 12 for SOF/RBV for 24 weeks', 'Treatment class', 'Naive', 'Experienced', 'Na\u00efve', 'Experienced', 'Without cirrhosis', '98%', '94%', '90%', '71%', 'With', '93%', '89%', '73%', '58%', 'Compensated', 'Cirrhosis', '3.3 Buprenorphine/naloxone', 'Buprenorphine/naloxone is used to treat opioid dependence. It is a combination of two medications,', 'buprenorphine and naloxone, in a 4:1 ratio.', 'Buprenorphine is a partial agonist at the -opioid receptor with a high affinity and slow dissociation from', 'these receptors. In individuals undergoing withdrawal from full opioid agonists, such as heroin,', 'buprenorphine ameliorates withdrawal symptoms by partially activating the -opioid receptors.', 'CRI 15-05 Protocol 13SEP2017', 'Page 16']\n\n###\n\n", "completion": "END"}